Plus Therapeutics, Inc. (PSTV)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Plus Therapeutics, Inc. (PSTV)
Company Performance

Current Price

as of Oct 16, 2024

$1.43

P/E Ratio

N/A

Market Cap

$8.43M

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Metrics

Overview

  • HQAustin, TX
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerPSTV
  • Price$1.43+1.42%

Trading Information

  • Market Cap$8.43M
  • Float97.45%
  • Average Daily Volume (1m)86,372
  • Average Daily Volume (3m)66,423
  • EPS-$3.05

Company

  • Revenue$5.51M
  • Rev Growth (1yr)-31.01%
  • Net Income-$2.94M
  • Gross Margin84.21%
  • EBITDA Margin-273.26%
  • EBITDA-$3.49M
  • EV$10.79M
  • EV/Revenue1.96
  • P/EN/A
  • P/S2.79
  • P/BN/A
Documents
SEC Filings
8-K (2024-09-06)
8-K (2024-08-15)
8-K (2024-08-14)
8-K (2024-06-07)
8-K (2024-06-04)
8-K (2024-05-20)
8-K (2024-05-15)
8-K (2024-05-09)
8-K (2024-03-14)
8-K (2024-03-13)
8-K (2024-03-05)
8-K (2023-11-20)
8-K (2023-10-31)
8-K (2023-08-14)
8-K (2023-05-16)
8-K (2023-04-28)
8-K (2023-04-21)
8-K (2023-04-20)
8-K (2023-03-13)
8-K (2023-03-03)
8-K (2023-02-23)
10-Q (2024-08-14)
10-Q (2024-05-15)
10-Q (2023-10-31)
10-Q (2023-08-14)
10-Q (2023-04-20)
10-K (2024-03-05)
10-K (2023-02-23)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-10-31)
Earnings Report (2023-08-14)
Factset
Factset Business Description
Factset Street Account
Plus Therapeutics reports new interim ReSPECT-GBM Phase 2 trial data at the Society for NeuroOncology Annual Meeting - 8-K ($2.63, 0.00) (2023-11-20T12:07:02Z)
Plus Therapeutics issues press release regarding previously reported orphan designation for Rhenium (186Re) ($1.36, 0.00) (2023-11-03T11:05:45Z)
Plus Therapeutics files common stock and pre-funded warrant offering of indeterminate amount - S-1 ($1.85, 0.00) (2023-11-22T21:11:41Z)
Plus announces financial updates and cash guidance for 2024; sees cash runway to H2 2025 ($1.91, 0.00) (2023-12-18T12:10:34Z)
FDA grants orphan drug designation to Plus Therapeutics' Rhenium (186Re) Obisbemeda for the treatment of breast cancer with leptomeningeal metastases (LM) ($1.38, +0.09) (2023-11-02T18:57:37Z)